(3-溴苯氧基)乙酸乙酯 | 138139-14-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (3-溴苯氧基)乙酸乙酯
• 英文名称: ethyl 2-(3-bromophenoxy)acetate
• 英文别名: ethyl 3-bromophenyloxyacetate
• CAS: 138139-14-7
• 化学式: C₁₀H₁₁BrO₃
• mdl: MFCD03945182
• 分子量: 259.1
• InChiKey: SOKSJIDLQWRXTN-UHFFFAOYSA-N

物化性质

• 沸点：
  296.7±15.0 °C(Predicted)
• 密度：
  1.418±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 2-(3-bromophenoxy)acetate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 2-(3-bromophenoxy)acetate
CAS number: 138139-14-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H11BrO3
Molecular weight: 259.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (3-溴苯氧基)乙酸乙酯 在 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 1.0h， 生成 3-溴苯氧基乙酸
  参考文献：
  名称：

  使用N-氟苯磺酰亚胺和光敏剂对芳氧基乙酸进行自由基脱羧氟化

  摘要：

  氟化甲氧基芳烃正在成为农用化学品和药物中的重要基序。开发了一种通过羧酸的直接氟脱羧合成单氟甲氧基芳烃的新技术，该技术使用光敏剂和 N-氟苯磺酰亚胺 (NFSI)。利用氧化性温和的氟转移剂 NFSI 能够合成氟甲基醚，而以前使用 Selectfluor 进行脱羧氟化是无法获得这些氟甲基醚的。机理研究与影响芳氧基乙酸氧化的光敏剂一致。

  DOI：

  10.1002/ejoc.201500038
• 作为产物：
  描述：

  间溴苯酚 、 溴乙酸乙酯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 (3-溴苯氧基)乙酸乙酯
  参考文献：
  名称：

  使用N-氟苯磺酰亚胺和光敏剂对芳氧基乙酸进行自由基脱羧氟化

  摘要：

  氟化甲氧基芳烃正在成为农用化学品和药物中的重要基序。开发了一种通过羧酸的直接氟脱羧合成单氟甲氧基芳烃的新技术，该技术使用光敏剂和 N-氟苯磺酰亚胺 (NFSI)。利用氧化性温和的氟转移剂 NFSI 能够合成氟甲基醚，而以前使用 Selectfluor 进行脱羧氟化是无法获得这些氟甲基醚的。机理研究与影响芳氧基乙酸氧化的光敏剂一致。

  DOI：

  10.1002/ejoc.201500038

文献信息

• [EN] DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS DIHYDROPYRIMIDINE ET UTILISATIONS DE CEUX-CI EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2019076310A1

  公开（公告）日：2019-04-25

  Provided herein are a dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B. Specifically, provided herein is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

  本文提供了一种二氢嘧啶化合物及其作为药物的用途，特别是作为用于治疗和预防乙型肝炎的药物的应用。具体而言，本文提供了具有化学式（I）或（Ia）的化合物，或其立体异构体、互变异构体、N-氧化物、溶剂合物、代谢物、药学上可接受的盐或其前药，其中化学式的变量如规范中所定义。本文还提供了使用具有化学式（I）或（Ia）的化合物，或其对映体、二对映异构体、互变异构体、水合物、溶剂合物或其药学上可接受的盐作为药物的用途，特别是用作治疗和预防乙型肝炎的药物。
• 二氢嘧啶类化合物及其在药物中的应用
  申请人：广东东阳光药业有限公司

  公开号：CN109678859B

  公开（公告）日：2020-12-29

  本发明涉及一种二氢嘧啶类化合物及其作为药物的用途，尤其是作为治疗和预防乙型肝炎的药物的应用。具体地说，本发明涉及通式(I)或(Ia)所示的化合物或其立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐或它的前药，其中各变量如说明书所定义。本发明还涉及通式(I)或(Ia)所示的化合物或其对映异构体、非对映异构体、互变异构体、水合物、溶剂化物或药学上可接受的盐作为药物的用途，尤其是作为治疗和预防乙型肝炎的药物的用途。
• Synthesis toward Bivalent Ligands for the Dopamine D₂ and Metabotropic Glutamate 5 Receptors
  作者：Mingcheng Qian、Elise Wouters、James A. R. Dalton、Martijn D. P. Risseeuw、René A. J. Crans、Christophe Stove、Jesús Giraldo、Kathleen Van Craenenbroeck、Serge Van Calenbergh

  DOI：10.1021/acs.jmedchem.8b00671

  日期：2018.9.27

  In this study, we designed and synthesized heterobivalent ligands targeting heteromers consisting of the metabotropic glutamate 5 receptor (mGluR5) and the dopamine D2 receptor (D2R). Bivalent ligand 22a with a linker consisting of 20 atoms showed 4-fold increase in affinity for cells coexpressing D2R and mGluR5 compared to cells solely expressing D2R. Likewise, the affinity of 22a for mGluR5 increased

  在这项研究中，我们设计和合成了针对由代谢型谷氨酸5受体（mGluR5）和多巴胺D 2受体（D 2 R）组成的异聚体的异二价配体。二价配体22A用由20个原子的连接体显示出对细胞共表达d亲和力增加4倍2 R和mGluR5的细胞相比表达单独d 2 R.同样地，所述亲和22A用于治疗mGluR5在共表达细胞中增加2倍。此外，在共表达D 2 R和mGluR5的细胞中，22a的mGluR5亲和力比其单价前体21a高5倍。这些结果表明22a能够桥接构成异二聚体的两个受体上的结合位点。同样，cAMP分析显示22a在稳定的D 2 R和mGluR5共表达细胞系中的效能比1高4倍。此外，分子建模揭示了22a能够通过在TM5-TM6界面之间通过并建立6个蛋白质-配体H键而同时结合两个受体。
• Plasminogen Activator Inhibitor-1 Inhibitor
  申请人：Miyata Toshio

  公开号：US20120022080A1

  公开（公告）日：2012-01-26

  The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.

  本发明提供了一种具有纤溶酶原激活物抑制剂-1抑制活性的新化合物，以及包括该化合物作为活性成分的PAI-1抑制剂。本发明还提供了一种对PAI-1活性具有抑制作用且在预防和治疗与PAI-1活性相关的各种疾病方面有效的药物组合物。
• Binding of E-selectin or P-selectin to sialyl Lewis.sup.x or
  申请人：Texas Biotechnology Corporation

  公开号：US05444050A1

  公开（公告）日：1995-08-22

  This invention relates to compounds that inhibit the binding of E-selectin and/or P-selectin to sialyl-Lewis.sup.x or sialyl-Lewis.sup.a presented on a cell surface having the general structure ##STR1## wherein X is selected from the group consisting of --(CH.sub.2).sub.n CO.sub.2 H, --O(CH.sub.2).sub.m CO.sub.2 H, --(CH.sub.2).sub.n O(CH.sub.2).sub.m CO.sub.2 H, --CONH(CH.sub.2).sub.m CO.sub.2 H, --CH(OZ)(CO.sub.2 H), --CH(Z)(CO.sub.2 H), --(CH.sub.2).sub.n SO.sub.3 H, --(CH.sub.2).sub.n PO.sub.3 D.sub.1 D.sub.2, --NH(CH.sub.2).sub.m CO.sub.2 H, --CONH(CHR.sub.6)CO.sub.2 H, (1-H-tetrazolyl-5-alkyl-), and --OH; R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, alkyl, halogen, --OZ, --NO.sub.2, --NH.sub.2 and --NHZ; R.sub.3 is selected from the group consisting of hydrogen, halogen, alkyl, --OZ and --NHZ; R.sub.4 is selected from the group consisting of hydrogen, halogen, alkyl, hydroxyl, hydroxyl-O-sulfate and --OZ; R.sub.5 is selected from the group consisting of hydroxyl, --CN, --N.sub.3, --NH.sub.2, --NHNH.sub.2, --NE.sub.1 E.sub.2, --NHE.sub.1, --NHCO(CH.sub.2).sub.n CO.sub.2 H, --S(CH.sub.2).sub.m CO.sub.2 H and --NHCHNHNH.sub.2 ; R.sub.6 is selected from the group consisting of hydrogen, alkyl, aralkyl, hydroxyalkyl, aminoalkyl, alkyl carboxylic acid and alkyl carboxamide; wherein n is 0 to 6, m is 1 to 6, p is 0 to 6, b is 0 to 2, Z is alkyl, aryl or aralkyl, D.sub.1 and D.sub.2 are independantly hydrogen or alkyl, E.sub.1 is alkyl or --(CH.sub.2).sub.8 CO.sub.2 H, and E.sub.2 is alkyl, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. This invention also relates to methods of inhibiting the binding of E-selectin and/or P-selectin to sialyl-Lewis.sup.x or sialyl-Lewis.sup.a presented on a cell surface using said compounds and to pharmaceutically active compositions comprising compounds that inhibit the binding of E-selectin to sialyl-Lewis.sup.x and to methods of treatment of septic shock, ARDS, Crohn's disease, chronic inflammatory diseases, such as psoriasis and rheumatoid arthritis, and reperfusion injuries that occur following heart attacks, strokes and organ transplants.

  这项发明涉及抑制E-选择素和/或P-选择素与细胞表面上呈现的唾液酸-Lewis.sup.x或唾液酸-Lewis.sup.a结合的化合物，其具有以下一般结构##STR1##其中X从--(CH.sub.2).sub.n CO.sub.2 H，--O(CH.sub.2).sub.m CO.sub.2 H，--(CH.sub.2).sub.n O(CH.sub.2).sub.m CO.sub.2 H，--CONH(CH.sub.2).sub.m CO.sub.2 H，--CH(OZ)(CO.sub.2 H)，--CH(Z)(CO.sub.2 H)，--(CH.sub.2).sub.n SO.sub.3 H，--(CH.sub.2).sub.n PO.sub.3 D.sub.1 D.sub.2，--NH(CH.sub.2).sub.m CO.sub.2 H，--CONH(CHR.sub.6)CO.sub.2 H，(1-H-四唑基-5-烷基-)和--OH中选择；R.sub.1和R.sub.2分别从氢，烷基，卤素，--OZ，--NO.sub.2，--NH.sub.2和--NHZ组中选择；R.sub.3从氢，卤素，烷基，--OZ和--NHZ组中选择；R.sub.4从氢，卤素，烷基，羟基，羟基-O-硫酸酯和--OZ组中选择；R.sub.5从羟基，--CN，--N.sub.3，--NH.sub.2，--NHNH.sub.2，--NE.sub.1 E.sub.2，--NHE.sub.1，--NHCO(CH.sub.2).sub.n CO.sub.2 H，--S(CH.sub.2).sub.m CO.sub.2 H和--NHCHNHNH.sub.2组中选择；R.sub.6从氢，烷基，芳基烷基，羟基烷基，氨基烷基，烷基羧酸和烷基羧酰胺组中选择；其中n为0至6，m为1至6，p为0至6，b为0至2，Z为烷基，芳基或芳基烷基，D.sub.1和D.sub.2独立地为氢或烷基，E.sub.1为烷基或--(CH.sub.2).sub.8 CO.sub.2 H，E.sub.2为烷基，以及其药学上可接受的盐，酯，酰胺和前药。这项发明还涉及使用所述化合物抑制E-选择素和/或P-选择素与细胞表面上呈现的唾液酸-Lewis.sup.x或唾液酸-Lewis.sup.a结合的方法，以及包含抑制E-选择素与唾液酸-Lewis.sup.x结合的化合物的药用活性组合物，以及用于治疗败血症休克，ARDS，克罗恩病，银屑病和类风湿性关节炎等慢性炎症性疾病以及心脏病发作，中风和器官移植后发生的再灌注损伤的治疗方法。